

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-38599

Aquestive Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction of Incorporation or organization)

30 Technology Drive, Warren, NJ 07059
(908) 941-1900

82-3827296
(I.R.S. Employer Identification Number)

(Address, Zip Code and Telephone Number of Registrant's Principal Executive Offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	AQST	Nasdaq Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The number of outstanding shares of the registrant's common stock, par value of \$0.001 per share (the "Common Stock"), as of the close of business on May 8, 2025 was 99,327,928.

(In thousands)

	Three Months Ended March 31,		Change	
	2025	2024	\$	%
Clinical Trials	\$ 2,101	\$ 3,578	\$ (1,477)	(41) %
Development and Manufacturing	16	134	(118)	(88) %
Product Research Expenses	566	241	325	135 %
Total Project Expenses	2,683	3,953	(1,270)	(32) %
Preclinical	256	83	173	208 %
R&D personnel costs	1,802	1,534	268	17 %
Consulting and outside services	76	5	71	N/M
Share-based compensation	330	170	160	94 %
Depreciation/amortization	15	20	(5)	(25) %
All other R&D	199	167	32	19 %
Total	\$ 5,361	\$ 5,932	\$ (571)	(10) %

The details of the project expenses are as follows:

	Three Months Ended March 31,							
	2025	2024		2025	2024		2025	2024
			% inc / dec			% inc / dec		% inc / dec
	Total			Anaphylm			AQST-108	
Clinical Trials	\$ 2,101	\$ 3,578	(41) %	\$ 1,922	\$ 2,975	(35) %	\$ 179	\$ 586
Development and Manufacturing	16	134	(88) %	—	119	N/M	16	15
Product Research Expenses	566	241	135 %	566	53	968 %	—	188
Total Project Expenses	\$ 2,683	\$ 3,953	(32) %	\$ 2,488	\$ 3,147	(21) %	\$ 195	\$ 789
								% inc / dec
							Libervant	
							\$ —	\$ 17
							—	—
							—	—
							\$ —	\$ 17

Total project expenses for Anaphylm decreased 21%, or \$659 over the comparable period in 2024. Anaphylm clinical trial expenses and development and manufacturing expenses decreased \$1,053 and \$119, respectively, over the comparable period in 2024, partially offset by increases in product research expenses of \$513. During the three months ended March 31, 2025 and 2024, clinical trial expenses for Anaphylm of \$1,922 and \$2,975, respectively, were primarily due to clinical trial costs associated with the continued advancement of the Anaphylm program. Product research expenses for Anaphylm increased by \$513, primarily related to expenses incurred for the preparation of the NDA filing. Total project expenses for AQST-108 decreased 75%, or \$594, over the comparable period in 2024. AQST-108 clinical trial expenses and product research expenses decreased \$407 and \$188, respectively over the comparable period in 2024 due the clinical study and feasibility work for AQST-108 performed in the prior year period.

R&D personnel costs increased by 17%, or \$268 over the comparable period in 2024, due to additional headcount. R&D share-based compensation increased by \$160, or 94% primarily related to the effect of RSU grants to R&D personnel. All other R&D expenses include rent, utilities, maintenance and other expenses and fees.

Selling, general and administrative expenses increased 78% or \$8,383 for the three months ended March 31, 2025 as compared to the same period in the prior year. The increase primarily represents regulatory fees related to the Anaphylm PDUFA fee of approximately \$4,310, higher legal fees of \$2,250, higher commercial spending of approximately \$2,130, higher regulatory and licensing fees of approximately \$505 related to the regulatory fee for Libervant, higher personnel costs of approximately \$440, and higher share-based compensation expenses of \$310, partially offset by decreases in severance costs of approximately 1,100 and lower insurance expenses of \$240.

Interest expense was \$2,782 and \$2,784 for the three months ended March 31, 2025 and 2024, respectively. These amounts represent interest incurred on the outstanding 13.5% Notes, and amortization of the debt discount and capitalized debt issuance costs.